Adherence to targeted oral anticancer medications

Discovery Medicine

Volumn 15, Issue 83, 2013, Pages 231-241

  Geynisman, Daniel M ^a   Wickersham, Karen E ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; CHRONIC MYELOID LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE DELIVERY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MEDICATION COMPLIANCE; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; GASTROINTESTINAL STROMAL TUMORS; HEALTH SERVICES ACCESSIBILITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUNG NEOPLASMS; MEDICATION ADHERENCE; NEOPLASMS;

EID: 84886248533     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Addeo R, Vincenzi B, Riccardi F, Febbraro A, Maiorino L, Incoronato P, Mabilia R, Bianco M, Russo E, Pisano A, S. DP. Multicenter observational study on adherence and acceptance of lapatinib treatment in patients with HER2+ metastatic breast cancer. J Clin Oncol 29(Suppl):abstr #e11102, 2011.
2. Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 30(5):482-487, 2012.
3. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care (Engl) 21(1):10-19, 2012.
4. Benjamin L, Cotte FE, Philippe C, Mercier F, Bachelot T, Vidal-Trecan G. Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment. Eur J Cancer 48(6):912-920, 2012.
5. Bosworth HB, Olsen MK, Grubber JM, Neary AM, Orr MM, Powers BJ, Adams MB, Svetkey LP, Reed SD, Li Y, Dolor RJ, Oddone EZ. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med 151(10):687-695, 2009.
6. Breccia M, Tiribelli M, Alimena G. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 84(1):93-100, 2012.
7. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 11(1):44-47, 2008.
8. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics 25(6):481-496, 2007.
9. Dasanu CA. Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs. J Oncol Pharm Pract 18(3):379-380, 2012.
10. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, Von Mehren M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27(19):3141-3147, 2009.
11. Dimatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42(3):200-209, 2004.
12. Ebrahim J, Han D, Hogeveen S, Trinkaus M, Fadhel E, Hon H, Kassam Z, Liu G, Simmons CE. Does drug cost drive drug adherence? The designer drug phenomenon. J Clin Oncol 30(Suppl):abstr #6084, 2012.
13. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35(5):626-630, 2011.
14. Escudier B. Metastatic RCC: moving towards a chronic disease. Oncology (Williston Park) 26(3):304, 306, 2012.
15. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22(16):3309-3315, 2004.
16. Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, Margeli M, Arcusa A, Prat A, Garcia M, Borras JM. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 107(8):1249-1256, 2012.
17. Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86(6):471-474, 2011.
18. Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, Macarthur RD, Chesney M, Friedland G, Mannheimer SB. Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS 24(3):395-403, 2010.
19. Gater A, Heron L, Abetz-Webb L, Coombs J, Simmons J, Guilhot F, Rea D. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 36(7):817-825, 2012.
20. Gebbia V, Bellavia G, Ferrau F, Valerio MR. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf 11(Suppl 1):S49-S59, 2012.
21. Gebbia V, Bellavia M, Banna GL, Russo P, Ferrau F, Tralongo P, Borsellino N. Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clin Lung Cancer, epub ahead of print, Jan. 9, 2013.
22. Graham DM, Bambury RM, Ismail JRM, O'Keefe M, Drake C, O'Shea A, Moylan EJ, Power DG, O'Reilly S. Oral anticancer therapy: Does the patient understand. J Clin Oncol 30(Suppl):abstr #e16506, 2012.
23. Guerin A, Chen L, Wu EQ, Ponce De Leon D, Griffin JD. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin 28(7):1155-1162, 2012.
24. Hauber AB, Gonzalez JM, Coombs J, Sirulnik A, Palacios D, Scherzer N. Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). Patient Prefer Adherence 5:307-314, 2011.
25. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120-4128, 2010.
26. Hess GP, Chi-Chang C, Hill JW, Liu Z, Gesme DH, Agarwala SS. Metastatic renal cell carcinoma: patient characteristics, treatment patterns, and schedule compliance in clinical practice. Kidney Cancer J 9(3):84-89, 2011.
27. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 130(1 Suppl):65S-72S, 2006.
28. Hotta K, Kiura K. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 11(7):991-997, 2011.
29. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733-3736, 2011.
30. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 87(11):1037-1045, 2012.
31. Jabbour EJ, Kantarjian H, Eliasson L, Megan Cornelison A, Marin D. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87(7):687-691, 2012.
32. Kartashov A, Delea TE, Sharma PP. Retrospective study of predictors and consequences of nonadherence with lapatinib (LAP) in women with metastatic breast cancer (MBC) who were previously treated with trastuzumab. J Clin Oncol 30(Suppl):abstr #e11067, 2012.
33. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215-220, 2006.
34. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, Perol D, Blay JY, French Sarcoma G. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11(10):942-949, 2010.
35. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 50(5):529-536, 2009.
36. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110-115, 1997.
37. Lucca JV, Hooper CL, Boucher J, Pedulla LV, Berry DL, Marcoux JP. A pilot study of direct care nurse (DCN) education to improve adherence and knowledge of erlotinib in patients with non-small cell lung cancer. J Clin Oncol 30(Suppl):abstr #e19637, 2012.
38. Macdonald N, Shapiro A, Bender C, Paolantonio M, Coombs J. Experiences and perspectives on the GIST patient journey. Patient Prefer Adherence 6:253-262, 2012.
39. Majem M, Pallares C. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clinical Transl Oncol 15(5):343-357, 2013.
40. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, De Lavallade H, Guallar C, Goldman J, Khorashad JS. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381-2388, 2010.
41. Mazzeo F, Duck L, Joosens E, Dirix L, Focan C, Forget F, De Geest S, Muermans K, Ma VaNL, Macdonald K, Abraham I, De Greve J. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res 31(4):1407-1409, 2011.
42. Mendez-Vidal MJ, Martinez Ortega E, Montesa Pino A, Perez Valderrama B, Viciana R. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31(Suppl 1):S19-S27, 2012.
43. Muluneh B, Alexander M, Deal AM, Deal M, Markey J, Neal J, Bernard SA, Valgus V, Dressler LG. Prospective evaluation of perceived barriers to medication adherence by patients on oral antineoplastics. J Clin Oncol 30(Suppl):abstr #6042, 2012.
44. Murphy AW, Cupples ME, Smith SM, Byrne M, Byrne MC, Newell J. Effect of tailored practice and patient care plans on secondary prevention of heart disease in general practice: cluster randomised controlled trial. BMJ 339:b4220, 2009.
45. Noens L, Van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, Van Eygen K, Macdonald K, De Geest S, Albrecht T, Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401-5411, 2009.
46. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist 17(4):536-542, 2012.
47. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 353(5):487-497, 2005.
48. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652-661, 2002.
49. Partridge AH, Lafountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556-562, 2008.
50. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602-606, 2003.
51. Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park) 26(3):290-301, 2012.
52. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1):56-66, 2009.
53. Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma: Part I-an updated review. PharmacoEconomics 29(4):315-329, 2011.
54. Skelly AH, Carlson J, Leeman J, Soward A, Burns D. Controlled trial of nursing interventions to improve health outcomes of older African American women with type 2 diabetes. Nurs Res 58(6):410-418, 2009.
55. Sokol MC, Mcguigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43(6):521-530, 2005.
56. Sommers RM, Miller K, Berry DL. Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer. Oncol Nurs Forum 39(4):E373-E379, 2012.
57. Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN, Stief CG. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy. Eur Urol 61(2):307-316, 2012.
58. Spoelstra SL, Given BA, Given CW, Grant M, Sikorskii A, You M, Decker V. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nurs 36(1):18-28, 2013.
59. Spoelstra SL, Given CW. Assessment and measurement of adherence to oral antineoplastic agents. Semin Oncol Nurs 27(2):116-132, 2011.
60. St Charles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, Deangelo DJ. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. ASH Annual Meeting Abstracts 114(22):2209, 2009.
61. Szmulewitz RZ, Ratain MJ. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther 93(3):242-244, 2013.
62. Timmers L, Boons CC, Mangnus D, Moes JE, Swart EL, Boven E, Smit EF, Hugtenburg JG. The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer 11:284, 2011.
63. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 24(18S):6119, 2006.
64. Vinayak S, Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology Williston Park) 27(1):38-44, 46, 48 passim, 2013.
65. Von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing. Cancer Treat Rev 37(4):291-299, 2011.
66. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189-1197, 1993.
67. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 3:47, 2010.
68. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'brien S, Reinke D, Rubino M, Saltz L, Walters RS. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 6(Suppl 3):S1-S14, 2008.
69. Wickersham K, Happ MB, Bender CM, Engberg SJ, Tarhini A, Erlen JA. Oncology Nursing Society's Connections: Advancing care through science poster abstracts (Abstract 1407539). Oncology Nursing Forum 39(6):E511-E547, 2012.
70. Winkeljohn DL. Oral chemotherapy medications: the need for a nurse's touch. Clin J Oncol Nurs 11(6):793-796, 2007.
71. Wolter P, Hendrickx T, Renard V, Mebis J, Debruyne PR, Wynendaele W, Schallier DCC, Vermeij J, Nielander A, Machiels JPH, Rottey S, Delande S, Goeminne JC, Schoffski P, Coster SD, Lacour VVF. Adherence to oral anticancer drugs (OAD) in patients (pts) with metastatic renal cancer (mRCC): First results of the prospective observational multicenter IPSOC study (Investigating Patient Satisfaction with Oral Anti-cancer Treatment. J Clin Oncol 30(Suppl):abstr #4622, 2012.
72. Wong SF, Nguyen CP, Bounthavong M, Bechtoldt K, Hernandez E. Outcome assessment of an oral chemotherapy management clinic: A preliminary report. J Clin Oncol 30(Suppl 34):abstr #105, 2012.
73. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 26(1):61-69, 2010.
74. Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 28(2):213-219, 2012.